All Posts

by John F. Heerdink, Jr. September 17, 2025

Lyft Teams Up with Alphabet’s Waymo for Nashville Robotaxi Rollout—Here’s the Timeline and Impact – ( $AMZN $LYFT $GOOG $TSLA $UBER $BIDU )

Waymo, Alphabet’s (GOOG) autonomous driving division, is deepening its push into commercial robotaxi operations through a new partnership with Lyft to launch driverless ride-hailing services in Nashville, Tennessee, beginning in 2026. In a joint announcement, the companies revealed that testing of Waymo’s all-electric, self-driving Jaguar I-Pace vehicles in the Nashville area would commence within months, with the aim to make the service available to the public next year.

Partnership Structure and Strategic Implications

The collaboration reflects a shift in Waymo’s model from being simply an operator of autonomous vehicles to becoming a broader technology provider in the mobility ecosystem. Under terms similar to Waymo’s recently expanded deals with Uber (UBER) in Atlanta and Austin, Lyft will take responsibility for key fleet support—including vehicle maintenance, cleaning, charging, and depot operations—through its Flexdrive subsidiary. However, a notable distinction is that, in Nashville, customers will be able to hail Waymo vehicles first through the Waymo app, with plans to expand availability to Lyft’s own app as the service matures.

This diverges from the Uber partnership, where consumers must use Uber’s platform for a chance at a self-driving ride. Lyft (LYFT), for its part, is investing in a dedicated autonomous vehicle facility to support the new fleet in Tennessee. Company leaders from both firms highlighted the synergies: Waymo praised Lyft’s established fleet management capability, while Lyft emphasized the scale and proven reliability of Waymo’s autonomous rides.

Market Context: AV Expansion and Growth Prospects

Waymo’s latest move is emblematic of the US robotaxi sector’s rapid scaling in 2025. The market, valued at about $1.5 billion this year, is projected to soar to over $400 billion by 2035, propelled by advances in autonomy and a flurry of strategic partnerships between technology giants and ride-hailing platforms. Waymo has already shifted from Phoenix—its initial testing ground—into large, complex metropolitan markets including San Francisco, Los Angeles, Austin, Miami, and Atlanta, with further ambitions targeting Denver, Dallas, Washington D.C., and additional US cities. Analysts predict that by 2030, there could be more than 35,000 robotaxis generating upwards of $7 billion in annual revenue, capturing approximately 8% of the US rideshare market.

Underlying Technology and Operational Milestones

Waymo has logged more than 100 million fully autonomous miles and hundreds of thousands of paid rides each week across its networks, reflecting years of iterative deployment and simulation-based enhancements to its AI. Executives note that successful commercial deployments in varied environments—from the broad, high-speed roads of Phoenix to the dense, unpredictable streets of San Francisco—have been crucial for scaling the system to new geographies efficiently.

Competitive and Regulatory Dynamics

Waymo’s expansion in Nashville underscores the competitive race with rivals such as Tesla (TSLA), Zoox (Amazon -AMZN), and Chinese players like Baidu (BIDU), all seeking to carve out their share of urban mobility. Regulatory adaptation and city-led pilot programs have emerged as critical enablers, with local governments establishing frameworks to integrate autonomous vehicles into public infrastructure and ensuring compliance with evolving safety standards.

Outlook

As Waymo and Lyft prepare to bring fully driverless rides to Nashville, the move marks another milestone in the commercialization of autonomous mobility in the United States. The sector’s explosive growth, high-profile partnerships, and ambitious technological advances are rapidly transforming the vision of everyday autonomous ride-hailing from a pilot concept into a mainstay of urban transportation.

Sources

by John F. Heerdink, Jr. September 16, 2025

Modular Medical Prepares for Pivot Pump FDA Filing and Market Debut – ( $MODD $TNDM )

Modular Medical (NASDAQ: MODD), a leader in innovative insulin delivery technology, is targeting the $3 billion adult “almost-pumpers” diabetes market with user-friendly, affordable patch pumps designed to simplify care for a population too often left behind by complex, expensive systems. Founded by Paul DiPerna—a seasoned medical device professional and microfluidics engineer who previously founded Tandem Diabetes (TDNM) and invented its celebrated t:slim insulin pump—Modular Medical leverages years of pioneering experience in diabetes technology.

Board Expansion and Leadership

In May 2025, Modular Medical appointed industry veteran Jeff Goldberg to its Board of Directors to accelerate market access and product strategy. Goldberg, who has held executive roles in both generic insulin innovation and drug-device combination product launches, brings a wealth of regulatory and operational knowledge. His track record, which includes serving as Chairman of Lannett Company and leading post-restructuring efforts and new insulin launches, aligns closely with Modular Medical’s disruptive approach to advancing diabetes care.

Regulatory Progress and Product Pipeline

On September 15, Modular Medical received IRB approval to initiate a pivotal 90-day feasibility study for its next-generation Pivot patch insulin pump—setting the company on a clear regulatory path toward its October 510(k) FDA submission and a potential commercial launch in 2026. CEO Jeb Besser underscored the platform’s focus on simplicity and affordability, spotlighting the large segment of adults who need, but often avoid, pump therapy due to legacy system limitations.

Product Transition and Market Focus

With the completion of MODD1 cartridge production in August, Modular Medical rapidly moved manufacturing resources toward the new Pivot system. This operational shift demonstrates a clear intent to capture the mainstream “almost-pumper” adult market with a solution that is lightweight, disposable, and easy to learn—a stark contrast to traditional, more cumbersome pumps.

Partnerships and Training Innovation

To further broaden adoption, the company partnered with Level Ex, introducing gamified educational modules for both clinicians and patients. These interactive tools, spotlighted at the ADCES 2025 conference, address barriers rooted in training and system complexity, aiming to streamline onboarding for providers and users alike.

Strategic Position

With Goldberg’s appointment and a leadership bench anchored by Paul DiPerna’s legacy in inventing industry-defining diabetes technologies, Modular Medical is well-positioned to democratize insulin delivery—offering affordable devices to wider segments of the population. Growing investor interest and strong early adopter feedback signal optimism as the company eyes global regulatory expansion and broad commercialization. Learn by viewing their latest powerpoint presentation.

Sources

by John F. Heerdink, Jr. September 16, 2025

Eli Lilly’s $5 Billion U.S. Manufacturing Bet: What It Means for Pharma and LLY Stock in 2025 ( $LLY $SPY $IBB )

Eli Lilly’s announcement of a $5 billion investment in manufacturing marks another chapter in the pharmaceutical giant’s escalating commitment to U.S. production infrastructure—a move emblematic of the sector’s race to harness domestic capacity and innovation amid ongoing global uncertainty and rising demand for advanced medicines. This strategic outlay follows a broader industry trend, where drugmakers are investing heavily in supply chain stability, resilient manufacturing, and digital transformation, all while contending with regulatory and demographic headwinds that threaten to erode margins and disrupt operations.

Manufacturing Expansion Reflects Shifting Industry Priorities

The pharmaceutical sector is leaning into domestic expansion, as illustrated by Lilly’s decision to more than double its U.S. manufacturing commitment since 2020, bringing its total investment to over $50 billion. This includes the construction of four new manufacturing sites dedicated to producing active pharmaceutical ingredients and advanced injectable therapies—central to addressing therapeutic areas ranging from cardiometabolic health to oncology and neuroscience. The initiative is expected to generate thousands of high-skilled jobs, bolstering the regional labor market and promising incremental improvements in supply chain resilience.

Broader Strategy and Competitive Context

Lilly’s investment dovetails with wider sector trends. More than 85% of biopharma executives in 2025 report escalating investment in AI, digital tools, and automation, hoping to offset operational volatility and reduce development timelines. Peer companies such as Amgen and Roche have already reported tangible improvements from data-driven automation and smart manufacturing, while others are ramping up collaborative alliances to target high-unmet-need therapeutic areas and drive portfolio innovation. These industry-wide shifts reflect both the race to commercialize science and the imperative to insulate supply chains from geopolitical and economic volatility.

Regulatory Backdrop and Pharma’s Defensive Moves

While Lilly’s aggressive infrastructure push speaks to confidence in U.S. manufacturing, the broader operating environment remains fraught with challenges. Regulatory winds—like the U.S. Inflation Reduction Act and Europe’s evolving pharmaceutical rules—are forecast to drive down revenues and reshape cost-benefit analyses for drug development, prompting firms to maximize operational efficiencies and focus on assets with clear commercial viability.

Stock Performance: A Bellwether within Pharma

Eli Lilly shares (NYSE: LLY) have mirrored the company’s operational ambitions, emerging as a standout performer in 2025’s competitive market. Recent trading saw LLY close at $748.19 on September 15th, reflecting strong momentum from the summer, where shares surged from below $700 in August to their current heights—underscoring investor confidence in Lilly’s vision, pipeline, and ability to navigate the sector’s shifting landscape. The rally further cements Lilly’s status as a bellwether in pharmaceutical innovation and execution.

Outlook

As drugmakers like Lilly invest heavily in technology-laden U.S. manufacturing, the sector is poised for both disruption and opportunity. The symbiosis of investment, innovation, and regulatory agility will determine which firms can sustain growth, meet intensifying therapeutic needs, and deliver shareholder value in a rapidly evolving landscape.

Sources

by John F. Heerdink, Jr. September 16, 2025

Turbo Energy Stock Surges as Company Wins Major Industrial Solar Storage Deal ( $TURB $XLE )

Turbo Energy S.A. (NASDAQ: TURB), a provider of AI-enabled solar energy storage solutions, secured a landmark $53 million contract to deploy 366 megawatt-hours (MWh) of solar battery storage capacity across more than ten industrial facilities in Spain, marking one of the company’s largest deals to date and sparking a surge in its Nasdaq-listed shares.

Contract Details and Industry Impact

The two-year agreement, awarded by a major construction industry group, calls for Turbo Energy’s SUNBOX Industry systems—introduced in 2024 and scalable from 30 kWh to 4,000 kWh of storage and 30 kW to 2,000 kW of power—to be installed and integrated at diverse industrial sites. The turnkey arrangement encompasses both physical infrastructure and Turbo Energy’s proprietary cloud-based AI energy management platforms, designed to dynamically optimize electricity purchases, reduce exposure to volatile energy prices, and bolster energy resilience—a critical consideration in the wake of recent regional grid disruptions.

Financial and Market Significance

For Turbo Energy, the project represents not just a financial windfall but also crucial validation within Europe’s rapidly growing energy storage sector. With global demand for commercial and industrial storage accelerating amid policy tailwinds and heightened energy price volatility, such a sizable contract positions the Valencia-based company as a credible contender for future large-scale opportunities. Recent reports project that the global energy storage market will grow at a compound annual rate exceeding 9% through 2030, adding further momentum to innovators in the space.

Technology and Strategic Positioning

Turbo’s SUNBOX Industry solution leverages artificial intelligence to anticipate market conditions and automate power usage, yielding operational efficiencies and cost savings for clients. The system provides configurable backup power, ensuring business continuity during outages or demand spikes, a feature increasingly sought by industrial customers. Company CEO Mariano Soria has suggested that successful implementation of this multi-site contract could open doors to similar projects across Europe, reinforcing Turbo’s aspirations of market leadership.

Recent Stock Performance and Broader Market Context

Investors reacted with enthusiasm, driving Turbo Energy (TURB) shares up by more than 100% in premarket trading and extending gains that have seen the stock climb over 600% year-to-date and over 400% today. Analysts and industry observers note that the deal’s comprehensive approach—with integrated software and hardware—may provide recurring revenue streams and enhance the company’s credibility among energy-intensive industries seeking to decarbonize and insulate against unpredictable markets.

In a market increasingly shaped by the urgency of energy resilience and the promise of artificial intelligence, Turbo Energy’s latest triumph illustrates the evolving narrative of the green technology sector: reliable innovation, sound execution, and strategic scale are drawing increased attention from both clients and capital alike.

by John F. Heerdink, Jr. September 15, 2025

McDonald’s Doubles Down on Supply Chain Resilience With $200 Million Agriculture Pledge ( $MCD $KO $WMT $SPY $DIA )

McDonald’s (MCD) is rolling out a high-profile $200 million commitment to regenerative agriculture in the United States, aiming to put sustainability and supply chain resilience at the center of its brand narrative. The seven-year project—announced in tandem with the National Fish and Wildlife Foundation—marks the largest such investment ever made by the Golden Arches in U.S. beef production and comes as the company faces mounting scrutiny over food sourcing and environmental practices.

Regenerative Agriculture and Supply Chain Strategy

The initiative, known as the Grassland Resilience and Conservation Initiative, is set to touch up to 4 million acres across 38 states. At its core, the project’s mandate is to bolster grazing techniques that enhance soil health, conserve water, and support wildlife habitats. Ranchers participating in the program will gain access to grants and technical guidance to adopt management practices like rotational grazing, controlling invasive species, and reseeding native grasses—practices that can lead to both environmental and economic benefits over time.

Industry Context and Supplier Involvement

In an environment of rising tariffs on international beef—40% on imports from Brazil, for example—McDonald’s investment is as much about prudent supply chain stewardship as it is about brand image. The company is bringing on board a cadre of major suppliers, including Cargill, Golden State Foods, Lopez Foods, OSI, and The Coca-Cola Company (KO), to co-fund the grants. The collaborative model echoes recent moves by rivals such as Chipotle, General Mills, and Walmart (WMT) to burnish their green credentials through agricultural reform.

Economic Realities and Industry Trends

While $200 million might seem headline-worthy, the sum constitutes less than 1% of McDonald’s 2024 total revenue of $25.9 billion, and, when amortized over seven years and spread across millions of acres, it amounts to approximately $7 per acre annually—a figure that underscores both the magnitude and the limitations of such corporate sustainability pledges. The National Fish and Wildlife Foundation will be responsible for administering the grants independently, aiming to ensure that the funds drive measurable change at the ranch level. Grant recipients are expected to be announced early next year.

Framing the Investment

McDonald’s North American supply chain chief, Cesar Piña, has positioned this move as a recognition of the fast-food leader’s “responsibility…to help safeguard our food systems for long-term vitality”. This investment folds into broader corporate ambitions to reduce emissions, conserve natural resources, and create a more resilient domestic food system—an increasingly critical undertaking as global supply chains are tested by both policy volatility and climate-driven risks.

Competitive Landscape and Broader Stakeholder Pressure

McDonald’s move is part of a growing trend among global food giants to invest in agricultural sustainability, with peers like Nestlé, PepsiCo, and Walmart launching similar efforts in recent years. These investments are not only about environmental stewardship but also about remaining competitive as consumers and investors increasingly weigh sustainability in their decision-making.

The Sum…

In summary, McDonald’s $200 million regenerative agriculture initiative is both a pragmatic hedge against supply chain uncertainty and an effort to align the company with rapidly evolving stakeholder expectations in the food industry. As the first grants begin to flow and the pilot programs are deployed, the broader industry will be watching closely to assess both the impact and the return on one of fast food’s boldest environmental bets.

Sources

by John F. Heerdink, Jr. September 15, 2025

Clinical Success Pushes GeoVax Into Spotlight as A Multi-Antigen Vaccine Leader – ( $GOVX $IBB $XBI )

GeoVax Labs (Nasdaq: GOVX), an Atlanta-based biotechnology firm, has garnered attention following the release of promising Phase 2 clinical data for its multi-antigen COVID-19 vaccine candidate, GEO-CM04S1, in patients with chronic lymphocytic leukemia (CLL). The findings, presented at the recent International Workshop on Chronic Lymphocytic Leukemia, have been described as a pivotal step for high-risk, immunocompromised populations often overlooked by traditional vaccine studies.

A Competitive Edge in the Vaccine Race

Unlike first-generation single-antigen mRNA vaccines, GEO-CM04S1 is engineered on a Modified Vaccinia Ankara (MVA) platform and targets both the spike and nucleocapsid proteins of SARS-CoV-2. This dual-targeting approach has translated to broader and more durable immune responses, a critical advantage given the disappointing durability of some widely adopted mRNA vaccines in vulnerable groups.

In the head-to-head portion of the Phase 2 trial, GEO-CM04S1 demonstrated notably superior T-cell and antibody responses in CLL patients compared to a standard mRNA vaccine comparator, which failed to meet defined immunogenicity thresholds. As a result, trial enrollment has been limited exclusively to GEO-CM04S1, underscoring growing scientific consensus on the need for robust cellular immunity in immune-dysfunctional populations.

Industry Tailwinds and Federal Priorities

GeoVax’s progress comes amid a larger industry inflection point. In August 2025, the U.S. Department of Health and Human Services began winding down major mRNA vaccine funding, citing the necessity for solutions with broader protection and greater durability against evolving respiratory pathogens. Agency priorities have shifted toward platforms—such as GeoVax’s MVA-based candidates—that promise multi-antigen, cross-variant effectiveness and scalable manufacturing.

GeoVax has responded by aligning its clinical and regulatory strategy to these national trends, leveraging programs like the Commissioner’s National Priority Voucher to further accelerate vaccine development.

Beyond COVID-19: An Expansive Pipeline

The company is not limiting itself to COVID-19. Pipeline advancements include ongoing trials for Gedeptin®, an experimental immunotherapy for head and neck cancer, and the anticipated clinical launch of GEO-MVA for Mpox and smallpox in late 2025. International regulatory feedback, especially from the European Medicines Agency, has been favorable, potentially streamlining approval timelines for new candidates.

The Sum…

GeoVax’s bet on broad, durable vaccines and adaptable immunotherapies & development of a scalable, innovative manufacturing base on U.S. soil-reflects both a bet on science—and a shrewd reading of the larger public health playbook. The firm’s emphasis on addressing unmet medical needs—especially among immunocompromised populations—coupled with its multi-pathogen pipeline, has also positioned it as a company to watch amid shifting industry and public sector priorities.

Sources

by John F. Heerdink, Jr. September 15, 2025

If You Invested $1,000 in Tesla’s IPO, Here’s What It’s Worth After Elon Musk’s $1B Stock Purchase – ( $TSLA $SPY $QQQ )

Investing $1,000 in Tesla (TSLA) stock at its June 2010 IPO would be worth over $23,290 today, reflecting the company’s staggering share appreciation since its debut at $17 per share and a current price of $395.94 per share. This remarkable journey encapsulates the transformation of Tesla from a niche electric vehicle startup to a dominant player in technology and renewables.

From Humble Beginnings to Market Titan

Back in 2010, Tesla’s IPO was met with skepticism as many doubted Elon Musk’s vision for mainstream electric vehicles. A $1,000 investment then bought about 58.8 shares, which have grown substantially in value with the company’s rise, making early investors some of the biggest winners in modern stock market history.

Today’s Headline: Musk Buys Big, Tesla Surges

Fast forward to September 2025, and Tesla is once again capturing Wall Street’s attention. Elon Musk made a rare open-market purchase of about $1 billion in Tesla stock, acquiring 2.57 million shares at prices between $372 and $396 last Friday. This bold move, Musk’s first such buy since 2020, sent TSLA shares up by roughly 7% in early trading, turning its year-to-date performance positive and giving the stock a 12% gain for 2025 after recovering from a nearly 45% plunge earlier in the year. Investors read Musk’s purchase as a robust show of faith in Tesla’s future—including its high-stakes bets on robotaxis and AI—even as the CEO warns of “a few rough quarters” ahead as U.S. EV incentives wind down. At the same time, Tesla’s board has floated a 10-year compensation plan potentially worth $1 trillion for Musk, underscoring the high expectations for Tesla’s growth.

Sources

by John F. Heerdink, Jr. September 11, 2025

Modular Medical Accelerates Campaign Targeting $3 Billion Adult Market with User-Friendly Pivot Insulin Pump – ( $MODD $PODD $MDT $TNDM )

Modular Medical (NASDAQ: MODD) is accelerating its campaign to transform insulin delivery for the adult “almost-pumpers” market—an estimated $3 billion segment of adults who have yet to embrace pump therapy due to the complexity and costs of traditional systems. In a series of recent breakthroughs, Modular Medical announced the successful completion of a clinical study of its FDA-cleared MODD1 insulin pump, with live feedback from nine clinicians with Type 1 diabetes. This user input is directly shaping the development of the Pivot pump, which is slated for FDA submission in October 2025 as the first tubeless, removable 3ml patch pump.

The company’s user-friendly and affordable design philosophy specifically addresses the unmet needs of “almost-pumpers,” aiming to make insulin delivery accessible and intuitive. The MODD1 incorporates microfluidics for low-cost insulin pumping, cell phone monitoring, and single-use disposable batteries, all geared toward simplicity and high-volume manufacturing. Modular Medical’s partnership with Level Ex brings gamified training modules to clinicians, aiming to accelerate learning and adoption rates while supporting a more inclusive model for diabetes care.

Milestones

Amid these milestones, Modular Medical’s operational prowess is evidenced by the swift transition of its manufacturing line from MODD1 cartridges to Pivot devices. Company leadership, led by CEO Jeb Besser and founder Paul DiPerna (the originator of Tandem’s t:slim pump), points to a culture of continuous iteration and market responsiveness.

Competitive landscape

The competitive landscape, meanwhile, is defined by established heavyweights such as Insulet (PODD) (Omnipod), Medtronic (MDT) (MiniMed 780G, Simplera CGM), and Tandem Diabetes Care (TNDM), as well as European entrants like Roche and Ypsomed. Innovations in the field increasingly focus on integrating pumps with continuous glucose monitoring (CGM), data analytics, and closed-loop systems. Modular Medical’s commitment to affordability, simplicity, and scalability is positioning it as a nimble disruptor in a space otherwise dominated by entrenched brands, all striving to meet the persistent demand for intuitive diabetes care.

In sum, Modular Medical’s latest string of advances and its focus on the vast “almost-pumpers” market—backed by user-driven design and scalable platforms—signal both opportunity and competitive pressure in the rapidly evolving insulin pump sector.

Sources

[1] Modular Medical Announces Completion of Clinical Study … https://www.morningstar.com/news/accesswire/1072005msn/modular-medical-announces-completion-of-clinical-study-of-modd1-pump

[2] Modular Medical unveils next-gen insulin patch pump https://www.drugdeliverybusiness.com/modular-medical-unveils-next-gen-insulin-pump/

[3] Modular Medical Announces Next-Generation Pivot Insulin … https://www.nasdaq.com/press-release/modular-medical-announces-next-generation-pivot-insulin-pump-adces-and-introduction

[4] Investor Relations https://ir.modular-medical.com/press-release-details.php?newsId=875ba311-11c8-4220-9d8a-1194854e6381

[5] Modular Medical Completes MODD1 Cartridge Production … https://www.ainvest.com/news/modular-medical-completes-modd1-cartridge-production-prepares-pivot-launch-2508/

[6] Modular Medical Completes Clinical Study of MODD1 … https://www.stocktitan.net/news/MODD/modular-medical-announces-completion-of-clinical-study-of-modd1-rv929eyrl7k2.html

[7] Modular announces next-gen Pivot insulin pump at ADCES https://biotuesdays.com/2025/08/08/modular-announces-next-gen-pivot-insulin-pump-at-adces/

[8] Modular Medical validates insulin pump for human-use … https://www.drugdeliverybusiness.com/modular-medical-validates-insulin-pump-production/

[9] Modular Medical Announces Completion of MODD1 … https://www.nasdaq.com/press-release/modular-medical-announces-completion-modd1-cartridge-production-and-commencement

[10] Modular Medical, Inc. (MODD) Stock Price, News, Quote … https://finance.yahoo.com/quote/MODD/

[11] The 9 largest diabetes technology companies in the world https://www.drugdeliverybusiness.com/largest-diabetes-tech-companies-in-the-world/

[12] Insulin Pump Market Report 2025 (Global Edition) https://www.cognitivemarketresearch.com/insulin-pump-market-report

by John F. Heerdink, Jr. September 10, 2025

Biotech Breakthrough: Serina Therapeutics Secures Insider Led Financing for SER-252 Registrational Trial in Neurology Pipeline – ( $SER $BHVN $XBI )

Serina Therapeutics (NYSE American: SER), a biotechnology firm headquartered at the HudsonAlpha Institute in Huntsville, Alabama, has rapidly advanced its position in the neurology pipeline by leveraging its proprietary POZ Platform™. Over the past several months, the company has unveiled a series of notable updates that underscore its clinical and financial momentum.

$20 Million Financing Fuels Parkinson’s Trial

On September 9, Serina announced a flexible financing agreement granting access to up to $20 million, led by Board Director Greg Bailey, MD. Structured as an unsecured convertible note distributed in five tranches, the funding is specifically designed to support the Phase 1b registrational study of SER-252, the company’s lead candidate targeting advanced Parkinson’s disease. Each tranche carries 100% warrant coverage, providing a potential additional $20 million if fully exercised. The financial structure enables Serina to deploy capital aligned with clinical trial milestones—an approach endorsed by the board and management as both prudent and essential given the complexities of late-stage drug development. Serina also continues to evaluate non-dilutive and strategic alternatives for expanding its funding base.

Greg_CircleHeadshot_Photo - Juvenescence

Greg Bailey (pictured above) is the Executive Chairman of Juvenescence, clinical-stage drug development company dedicated to extending healthy lifespan through innovative medicines, which he co-founded in 2017. He also led the seed financing of Biohaven Pharmaceuticals Holding Company Ltd. and joined the board in 2014. He is also a board director of public companies Biohaven Pharmaceuticals (NYSE – BHVN) and Portage Biotech (NASDAQ – PRTG). Dr. Bailey also founded and served as a director of a number of private and public companies and previously served as a managing partner of Palantir Group, Inc., a merchant bank involved in a number of biotech company startups and financings. He was also an independent director of Medivation, Inc. (MDVN:NASDAQ), acquired by Pfizer in 2016. Dr. Bailey practiced emergency medicine for ten years before entering finance. Dr. Bailey received his M.D. from the University of Western Ontario.

Progress on SER-252 and Regulatory Milestones

The core of Serina’s clinical push is SER-252, a next-generation formulation of apomorphine leveraging the POZ platform for continuous dopaminergic stimulation via subcutaneous injection. This technology aims to address the unmet needs of approximately 180,000 advanced Parkinson’s patients in the U.S. and Europe who struggle with motor fluctuations and limited on-time control under current therapies. Following recent FDA feedback, Serina plans to submit its IND application in Q4 2025, with patient dosing in Australia expected to begin in parallel. U.S. enrollment is projected for Q1 2026. The Phase 1b study will use a randomized, double-blind, placebo-controlled design to evaluate safety, pharmacokinetics, and exploratory efficacy, including established motor function endpoints. Strategic delivery partnerships, such as with Enable Injections’ enFuse™ wearable platform, are expected to further improve patient experience.

Corporate Positioning and Expansion

Serina’s recent news cycle has also covered corporate governance and development. Grants of inducement stock options to new employees reflect long-term alignment with shareholders, while the upcoming annual stockholders meeting in November signals continued transparency and engagement. The company’s investor communications emphasize its ability to progress even amid broader biotech sector volatility. Other pipeline candidates—including SER-270 for tardive dyskinesia (TD)—remain on track, with IND-enabling studies anticipated to commence shortly. TD is a disabling and often stigmatizing movement disorder caused by long-term exposure to antipsychotic medications. It predominantly affects those with chronic psychiatric conditions such as schizophrenia and bipolar disorder who may have difficulty adhering to complex daily medication regimens. While oral VMAT2 inhibitors are the only approved class for TD, uptake remains modest due to underdiagnosis, low disease awareness among clinicians, and the challenges of ensuring daily medication adherence in complex, high-risk populations. It is estimated that fewer than 30% of U.S. TD patients are diagnosed, and less than half of those receive pharmacologic treatment. Despite these challenges, the U.S. TD market exceeded $3.7 billion in sales in 2024, driven by increased recognition and broader reimbursement. Analysts project the market to grow to $5.4 billion by 2030, underscoring the significant opportunity for differentiated therapies that address adherence, access, and administration barriers.

Spotlight on the POZ Platform

The foundation for Serina’s approach is the POZ Platform™, which is based on a synthetic, water soluble, low viscosity polymer called poly (2-oxazoline). During the synthesis steps, a predictable amount of drug is incorporated on the backbone of the polymer using pendant alkyne groups and metal catalyzed “click chemistry”. The POZ Platform ™ technology provides greater control in drug loading, and the rate of release of attached drugs can often be more precisely controlled. Drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood. Further, the technology is optimized for small molecules and can also be applied to other classes of molecules including proteins and peptides. The application of the platform has been further expanded to optimize the performance of antibody drug conjugates and lipid nanoparticles. This versatility remains a central theme in Serina’s corporate narrative and continues to attract both investor and strategic partner attention.

Featured Presentation From Serina August 2025

Learn more by reviewing Serina’s current powerpoint, titled Next Generation Drug Product Optimization Platform. Enabling Improvements of Multiple Drug Modalities.

The Sum…

Serina Therapeutics’ (NYSE American: SER) recent momentum is emblematic of a biotech sector increasingly focused on targeted innovation and careful capital allocation—and will be closely watched by both Wall Street and the neurological disease community in the lead-up to its key regulatory inflection points.

Sources

[1] Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference https://www.globenewswire.com/news-release/2025/09/08/3145916/0/en/Serina-Therapeutics-to-Present-at-the-H-C-Wainwright-27th-Annual-Global-Investment-Conference.html

[2] Serina Therapeutics Secures Up to $20 Million to Advance https://www.globenewswire.com/news-release/2025/09/09/3147306/0/en/Serina-Therapeutics-Secures-Up-to-20-Million-to-Advance-Registrational-Trial-of-SER-252-in-Parkinson-s-Disease.html

[3] Serina Therapeutics – Investor Relations https://investors.serinatherapeutics.com/overview/default.aspx

[4] Homepage – Serina Therapeutics, Inc. https://serinatherapeutics.com

[5] SER – Serina Therapeutics Latest Stock News & Market Updates https://www.stocktitan.net/news/SER/

[6] Pipeline – Serina Therapeutics, Inc. https://serinatherapeutics.com/pipeline/

[7] Science – Serina Therapeutics, Inc. https://serinatherapeutics.com/science/

[8] [8-K] Serina Therapeutics, Inc. Reports Material Event – Stock Titan https://www.stocktitan.net/sec-filings/SER/8-k-serina-therapeutics-inc-reports-material-event-874547a2d069.html

by John F. Heerdink, Jr. September 10, 2025

Oracle Stock Skyrockets Over 40% as AI-Powered Cloud Contracts Hit Record Highs ( $ORCL $SPY $NVDA )

Oracle’s stock (ORCL) experienced a historic rally today, surging as much as 42% following news of unprecedented demand for its AI-driven cloud infrastructure and record-breaking contract wins. This marks Oracle’s largest single-day gain since the 1990s and sets a record for companies with market capitalizations exceeding $500 billion.

Key Developments

Oracle announced its fiscal first-quarter results, revealing four new multibillion-dollar contracts, including major AI and cloud clients. The company’s backlog of remaining performance obligations (RPO) grew by 359% year-over-year to $455 billion, and guidance for fiscal 2026 anticipates $18 billion in cloud infrastructure revenue, accelerating to $144 billion annually by fiscal 2030. Investor enthusiasm remains high due to the scope of Oracle’s new cloud contracts and its strengthened position in AI and cloud services.

Stock Performance

Today, Oracle shares soared as high as $341.93, reflecting optimism about its AI strategy and cloud transformation. Over the last 12 months, the stock has appreciated approximately 74%–94%, with more than half the gain realized in the first half of 2025 as Oracle revealed its visionary outlook and secured transformative deals.

Industry Context

Oracle is emerging as a major infrastructure backbone for clients training and deploying large AI models, benefiting from aggressive hardware acquisitions (notably Nvidia (NVDA) GPUs) and proprietary networking technology. These advances put Oracle on competitive footing with Microsoft, Amazon, and Google in the booming AI cloud market. The company is now the 10th most valuable in the S&P 500, driven by analyst upgrades and a bullish industry outlook. Oracle’s transformation additionally signals growing investor conviction that the company will be at the center of the next wave of technology innovation, powered by AI and cloud infrastructure.

Partnership Structure and Strategic Implications

Market Context: AV Expansion and Growth Prospects

Underlying Technology and Operational Milestones

Competitive and Regulatory Dynamics

Outlook

Sources

Board Expansion and Leadership

Regulatory Progress and Product Pipeline

Product Transition and Market Focus

Partnerships and Training Innovation

Strategic Position

Sources

Manufacturing Expansion Reflects Shifting Industry Priorities

Broader Strategy and Competitive Context

Regulatory Backdrop and Pharma’s Defensive Moves

Stock Performance: A Bellwether within Pharma

Outlook

Sources

Contract Details and Industry Impact

Financial and Market Significance

Technology and Strategic Positioning

Recent Stock Performance and Broader Market Context

Regenerative Agriculture and Supply Chain Strategy

Industry Context and Supplier Involvement

Economic Realities and Industry Trends

Framing the Investment

Competitive Landscape and Broader Stakeholder Pressure

The Sum…

Sources

A Competitive Edge in the Vaccine Race

Industry Tailwinds and Federal Priorities

Beyond COVID-19: An Expansive Pipeline

The Sum…

Sources

From Humble Beginnings to Market Titan

Today’s Headline: Musk Buys Big, Tesla Surges

Sources

Milestones

Competitive landscape

Sources

$20 Million Financing Fuels Parkinson’s Trial

Progress on SER-252 and Regulatory Milestones

Corporate Positioning and Expansion

Spotlight on the POZ Platform

Featured Presentation From Serina August 2025

The Sum…

Sources

Key Developments

Stock Performance

Industry Context

Sources

Your Guide To Staying Informed In The Markets